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Incidence and epidemiology
Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women, respectively, thus representing the seventh most common cancer in men, and the tenth most common cancer in women [1] . However, available statistics include not only renal parenchymal tumours, but also urothelial cancer of the renal pelvis; renal cell carcinoma (RCC) accounts for ∼80% of all kidney cancers.
After over two decades of increasing rates, RCC incidence trends worldwide have shown signs of plateauing in recent years. Furthermore, kidney cancer mortality rates overall have levelled. These patterns are consistent with reports of incidental diagnosis and downward shift of tumour stage and size; indeed, the widespread use of non-invasive radiological techniques [e.g. ultrasonography (US), computed tomography (CT)], allows the frequent detection of early and small RCCs, which are potentially curable.
Beyond well-known risk factors for RCC, such as cigarette smoking, obesity and hypertension, evidence is accumulating to suggest an aetiological or, on the contrary, a protective role, for additional factors [2] , such as trichloroethylene. In a recently published case control study of 699 RCC patients and 1001 frequency-matched controls, consumption of caffeinated coffee was found to be associated with reduced risk of RCC; interestingly, decaffeinated coffee was associated with an increased risk for aggressive clear cell RCC (ccRCC) [3] .
Furthermore, RCC also appears to be more common in patients with end-stage renal failure or acquired renal cystic disease, and in patients on dialysis, those who have had kidney transplantation or those with tuberous sclerosis syndrome.
Approximately 2%-3% of all RCCs are hereditary and several autosomal dominant syndromes are described, each with a distinct genetic basis and phenotype, the most common one being von Hippel-Lindau (VHL) disease. Patients with multiple and bilateral lesions and/or other related affections should be tested for these germline mutations since it is important that they are recognised. A renal tumour core biopsy provides histopathological confirmation of malignancy with high sensitivity and specificity; it is especially recommended before treatment with ablative therapies [III, B] as well as in patients with metastatic disease before Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdz056/5345645 by guest on 02 April 2019 starting systemic treatment [III, B]. Complications (e.g. bleeding or tumour seeding) are rare or even exceptional (as in the case of tumour seeding) [4] , while diagnostic accuracy remains high [5] . The final histopathological diagnosis, classification, grading and evaluation of prognostic factors are based on the nephrectomy specimen when available.
Diagnosis and pathology/molecular biology

Pathology assessment
The last edition of the World Health Organization (WHO) histological classification of renal tumours has been reported in 2016 (Table 1) , and was based on tumour histology, chromosomal alterations and molecular pathways [6] . ccRCCs represent 80% of malignant renal tumours in adults, with the remaining 20% corresponding to several histological subtypes with different histological, molecular and cytogenetic profiles [7] . Papillary and chromophobe RCCs account for 80% of non-ccRCCs.
Papillary RCCs which represent a heterogeneous disease are characterised by:
 type 1 RCCs more frequently associated to MET or epidermal growth factor receptor (EGFR) mutations; and  type 2 RCCs often unique tumour with an aggressive phenotype that are associated with SETD2 mutations, CDKN2A mutations or TFE3 fusions [8] .
In papillary type 2 with familial history of papillary RCC, a fumarate hydratase (FH) mutation should also be investigated.
The main goal in diagnosis of chromophobe RCC, especially in the eosinophilic histological subtype, is the differential diagnosis with oncocytoma. Chromophobe RCCs have diffuse positivity for cytokeratin 7 (CK7), whereas oncocytomas are negative or present focal positivity for CK7. Moreover, chromophobe RCCs display more frequent chromosome loss but fewer somatic mutations. The most frequently mutated gene is tumour suppressor protein 53 (TP53) (32%), and the most frequent oncogenic pathways involved in such tumours are mammalian target of rapamycin (mTOR) pathways (23%), including alterations of phosphatase and tensin homologue (PTEN) [9] . reported cases of TFEB-amplified RCCs that occur in older patients. These tumours presented high-grade eosinophilic cells with necrosis and papillary or pseudopapillary architecture. The expression of melanocytic markers is variable and FISH analyses revealed high levels of TFEB gene amplification. The prognosis of such tumours is poor with usually advanced stage and metastatic outcome [10] .
Collecting duct carcinoma (CDC) or Bellini duct carcinoma remains a highly aggressive RCC arising from the renal collecting tubules. A recent specific gene expression signature showed that CDC appears to be a unique entity among kidney cancers [11] . Moreover, these tumours are characterised by an immune profile with an average of 22% of tumour-infiltrating lymphocytes [12] . 
Biology
Beyond the classical one gene-one histology paradigm, a more complex biological classification of RCC (and especially of its clear cell histotype) is emerging [14] .
First, RCC proved to be an extremely heterogeneous disease [15] ; beyond the seminal genetic alteration (mutation, deletion or hypermethylation) of the VHL tumour suppressor gene, which is present in the vast majority of sporadic RCCs, other genetic alterations may occur, especially over time [16] , contributing to worsen the prognosis of patients harbouring these tumours. Notably, three of these other genes (PBRM1, BAP1 and SETD2) are located on the same short arm of chromosome 3
where the VHL gene is also located.
On the contrary, some RCCs are characterised by mutations in the mTOR pathway, and especially in the highly conserved FAT (FRAP, ATM, TTRAP) and kinase domains of the MTOR gene; these cancers have been defined as metabolic RCCs [17] .
Finally, according to another comprehensive molecular characterisation of papillary RCCs, type 1 and type 2 papillary RCCs were shown to be clinically and biologically distinct. Alterations in the MET pathway were indeed associated with type 1 and activation of the NRF2-ARE pathway was associated with type 2, while CDKN2A loss and a CpG island methylator phenotype in type 2 contributed to convey a poor prognosis [8] .
Staging and risk assessment Staging
The Union for International Cancer Control (UICC) tumour, node and metastasis (TNM) 8 staging system should be used ( Table 2) .
Risk assessment
The natural clinical course varies in RCC, which has led to the development of different prognostic models for the assessment of the patient's individual risk. Extent of disease, histology, grading and clinical factors have been recognised as having prognostic value in RCC and may be used in localised or in metastatic disease [6] . The most recent modifications of the stage, size, grade and necrosis (SSIGN) score [18] (Table 3 ) and the University of California Los Angeles Integrated Staging System (UISS) ( Table 4 ) [19] score are frequently used.
However, among different prognostic scores, a concordance of 0.68-0.89 for cancerspecific survival (CSS) and 0.74-0.82 for recurrence-free survival (RFS) was reported [20] , indicating that a plateau has been reached for prognostication with available models. Hence, no clear preference for a specific prognostic model may be given.
Advanced disease
The Memorial Sloan Kettering Cancer Center (MSKCC) system was the gold standard for the risk assessment during cytokine treatment in metastatic RCC (mRCC) [21] , and it is still commonly used. Further refinement was introduced with the International Metastatic RCC Database Consortium (IMDC) score, which extended the previous factors to a total number of six in order to increase concordance [22] :  Karnofsky performance status (PS) < 80%;
 Haemoglobin level below the lower limit of normal;
 Time from diagnosis to treatment < 1 year;  Corrected calcium above the upper limit of normal;  Platelets greater than the upper limit of normal; and  Neutrophils greater than the upper limit of normal.
A recent evaluation of this model in second-line treatment underscored its predictive value in previously treated mRCC [23] (Table 5) . Interestingly, this model is also applicable in further lines of therapy as well as in non-clear cell histology. Gene signatures can be used to detect different risk groups in RCC. ClearCode34 is a 34-gene expression panel which proved able to classify ccRCC into two subtypes, clear cell A (ccA) and clear cell B (ccB), significantly associated with relapse-free survival and CSS, as well as overall survival (OS) [24] . Another gene signature, based on a 16-gene assay, was shown to improve prediction of RFS in localised RCC when compared with the SSIGN score according to the Leibovich score (concordance: 0.81 versus 0.74) [25] .
Molecular prognostication and biomarkers
Some gene mutations have also been reported as prognostic. The University of Texas Southwestern group identified distinct clinical outcomes in mutation-defined subtypes of ccRCC : a high-risk BAP1-mutant group and a favourable PBRM1mutant group [26] . Notably, 80% of patients from both the development and the validation cohorts had localised (or locoregional) disease.
In the metastatic setting, the immunohistochemical expression of programmed cell death-ligand 1 (PD-L1) is presently under the spotlight, although the results available so far are still controversial. In 2016, a systematic review and meta-analysis of six studies and 1323 cases clearly demonstrated a negative prognostic role of elevated level of PD-L1 tumour expression in RCC [27] , although discrepancies between PD-L1 expression between the primary tumour and the metastases have been reported.
A possible predictive value of PD-L1 expression remains controversial, although recently, PD-L1 tumour expression was shown to be able to identify patients benefiting from a combination of two immune-checkpoint inhibitors [28] . In addition, angiogenesis, T-effector/interferon (IFN)-γ response and myeloid inflammatory gene expression signatures have been suggested to predict response to vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) and immunotherapy [29] . As a whole, PD-L1 expression should not be routinely used but is a putative biomarker for future treatment selection because of remaining unanswered issues related to the different tests and cut-offs used, to the cells where PD-L1 expression should be checked and to the role of PD-L1 expression heterogeneity (e.g. between different primary tumour sites, or between primary tumour and its metastases).
Other putative markers such as circulating DNA (cDNA), microRNA or DNA methylation status were shown to have prognostic relevance in RCC and warrant 9 future investigation. Overall, these data indicate that molecular analysis may provide additional benefit to already established clinical and histo-anatomical parameters, which may lead to an individual risk assessment in the future. Currently, no specific molecular marker can be recommended for clinical use. Systematic reviews of RFA and PN suggest a long-term CSS for RFA, equal to PN with a low metastasis rate but slightly higher local recurrence rate compared with PN and CA [30] . The quality of the available evidence prevents definitive conclusions regarding morbidity and oncological outcomes for RFA and CA [III].
Management of local/locoregional disease
Role of surgery and local therapy
Active surveillance is an option in elderly patients with significant comorbidities or those with a short life expectancy and solid renal tumours measuring < 40 mm. The growth of renal tumours (mean 3 mm/year) is low in most cases and progression to metastatic disease is reported in 1%-2% [31] . Renal biopsy is recommended to select patients with small masses for active surveillance [III] with high accuracy, especially because of the incidence of non-malignant tumours in this setting [4, 5] .
T2 tumours (> 7 cm)
Laparoscopic RN is the preferred option.
Locally advanced RCC (T3 and T4)
Open RN remains the standard of care, even though a laparoscopic approach can be considered.
Systematic adrenalectomy or extensive lymph node dissection is not recommended when abdominal CT shows no evidence of adrenal or lymph node invasion.
The evidence regarding management of venous tumour thrombus is based on retrospective studies with significant risks of bias and confounding. Resection of venous thrombi is challenging and associated with a high risk of complications.
Surgical intervention should be considered, but the most effective approach remains unknown and outcome depends on tumour thrombus level [III].
Adjuvant therapy
Several RCTs of adjuvant sunitinib (S-TRAC, ASSURE), sorafenib (ASSURE) and pazopanib (PROTECT) have been reported [32] [33] [34] . Only S-TRAC was positive for its primary endpoint, disease-free survival (DFS) by independent review, but without any OS benefit. This result led to approval of sunitinib by the United States Food and Drug Administration (FDA). The European Medicines Agency (EMA) has not approved adjuvant therapy with any of these drugs because of the imbalance between risk and clinical benefit. A recent pooled analysis of S-TRAC, ASSURE and PROTECT did not reveal a statistically significant effect between adjuvant VEGFRtargeted therapy and an improved DFS or OS in patients with intermediate-/high-risk local or regional fully resected RCC [35] . Improvement in DFS may be more likely with the use of full-dose regimens and in high-risk disease, but adjuvant treatment was associated with high-grade adverse events (AEs).
Neoadjuvant approaches are experimental and should not be proposed outside of clinical trials. Attempting to downsize venous tumour thrombi with systemic targeted therapy cannot be recommended.
Management of metastatic disease
Role of surgery and local therapy
In the cytokine era, cytoreductive nephrectomy (CN) was recommended in patients with good PS [I, A] [36] . Two randomised trials (CARMENA and SURTIME) investigated the role and sequence of CN in the era of VEGFR-targeted therapy [37] [38] . Results of CARMENA and SURTIME should not be used to abandon CN in patients with low volume metastatic disease, a good PS and favourable and intermediate risk,
who are candidates for initial observation. In fact, both trials recruited patients with high median metastatic volumes (42% of total tumour burden for CARMENA) who needed to start sunitinib.
Metastasectomy and other local treatment strategies including whole-brain radiotherapy (WBRT), conventional radiotherapy (RT), stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), CyberKnife ® RT and hypofractionated RT can be considered and carried out for selected patients after multidisciplinary review. A systematic review of 16 studies including 2350 patients sought to identify the evidence base for local treatment strategies of metastases from RCC [39] . The results consistently point towards a benefit of complete metastasectomy for OS and CSS, but there is selection bias and the results have to be interpreted with caution.
No systemic treatment is recommended after metastasectomy.
No general guidelines can be given to identify cases to refer for local treatment of metastases. Patient selection should be discussed in a multidisciplinary team. Good PS, solitary or oligometastases, metachronous disease with disease-free interval > 2 years, absence of progression on systemic therapy, low or intermediate Fuhrmann grade and complete resection have been associated with favourable outcome after local treatment of metastases from RCC.
Systemic treatment for ccRCC
Recommendations mainly relate to clear cell histology, since most of the pivotal trials have been conducted in this common histological subtype. In addition, recommendations will differ according to risk stratification (see above).
The proper time to start systemic therapy is not well defined. Because of an indolent course of some RCCs a period of observation before starting treatment should be considered, especially in patients with limited tumour burden and few symptoms.
Indeed, the outcome of patients who crossed over to an active agent after a brief period of treatment with placebo, within placebo-controlled phase III trials, indirectly supports this option [II, C]. The safety of observation has been suggested by retrospective studies and confirmed by a prospective study [40] .
First-line treatment
An algorithm for first-line systemic treatment in ccRCC is presented in Figure 1 .
Three vascular endothelial growth factor (VEGF)-targeted agents have demonstrated efficacy in pivotal phase III trials, mostly focused on good and intermediate patients:
bevacizumab (combined with IFN), sunitinib and pazopanib [41] [42] [43] . All three drugs have been registered based on improvement of progression-free survival (PFS) over either IFN or placebo. Furthermore, pazopanib has been shown not to be inferior to sunitinib in a large phase III trial [44] . Efficacy of both sunitinib and pazopanib has been confirmed by real-world evidence studies, and these two TKIs are currently the most commonly used treatments in good-and intermediate-risk patients. In addition, tivozanib, a selective VEGF inhibitor, has been shown to improve PFS and response rate versus sorafenib, especially in good-risk patients [45] , and is EMA-approved for first-line treatment.
Temsirolimus has been tested in a phase III study in poor-risk patients only versus IFN, demonstrating evidence of improved OS in this patient population [46] .
Recently, a large phase III study demonstrated that the combination of nivolumab and ipilimumab was superior to sunitinib in intermediate-and poor-risk patients, but not in good-risk patients [28] . In the intermediate-and poor-risk population, the combination improved OS as well as response rate, with a high complete response rate (9.4%). By contrast, both response rates and PFS were higher with sunitinib in the good-risk group.
In addition to these large phase III trials, some efficacy has been reported with sorafenib, high-dose interleukin-2 (IL2) and low-dose IFN combined with bevacizumab, and such therapies should be considered as possible options when the standard treatments are not available. Similarly, single-agent IFN-alpha, as the inferior arm of three RCTs, should no longer be regarded as a standard option.
Finally, based on a randomised phase II study, cabozantinib appeared to be superior to sunitinib in terms of PFS and response rate and has been approved by the EMA in the first-line setting in intermediate-and poor-risk patients [47] .
Based on the recent data, it appears useful to provide recommendations based on risk classification [see level of evidence (LoE) in Figure 1 ].
In good-risk patients, VEGF-targeted agents should remain the standard of care with sunitinib, pazopanib or bevacizumab combined with IFN. Tivozanib is another standard of care when available. In poor-risk patients, similarly, combination of nivolumab and ipilimumab is the new standard of care. Among targeted agents, cabozantinib is an attractive option when available. In this specific patient population, temsirolimus remains an option, as well as TKIs (sunitinib or pazopanib). However, in some poor-risk patients with poor Eastern Cooperative Oncology Group (ECOG) PS, only palliative care should be recommended.
Second-line treatment
An algorithm for second-line systemic treatment in ccRCC is presented in Figure 2 .
Evidence that TKIs are active after cytokines has been seen with sorafenib, pazopanib, axitinib and tivozanib. Sunitinib also has activity is this setting. Any of these agents can be used after cytokines. However, since VEGF-targeted therapy is now the first-line standard of care, the number of patients treated with cytokines is decreasing.
After first-line treatment with VEGF-targeted therapy:
 Both axitinib and everolimus are active [48, 49] . Both drugs have shown significant improved PFS over sorafenib (axitinib) or placebo (everolimus); and  Based on recent phase III trials, sorafenib can also be used as an option.
However, second-line treatment has been dramatically modified by the report of two large trials showing improvement in OS with nivolumab and cabozantinib [50] [51] [52] over everolimus. Both trials showed very significant improvement in OS and response rate, while PFS was improved only in the cabozantinib trial. In both trials, patients could be treated after either one or two TKIs.
Obviously, availability of these two drugs is still heterogenous, and several situations should be differentiated:
 If only nivolumab is available, it should be recommended;
 If both nivolumab and cabozantinib are available, either drug is recommended;
 The combination of lenvatinib and everolimus showed PFS and OS benefit over everolimus based on a randomised study of 150 patients [53] and is FDA and EMA-approved. However, based on the size of this study, this combination should be considered as an acceptable option, primarily when nivolumab or cabozantinib cannot be delivered;
 If none of these drugs is available, either everolimus or axitinib can be used.
The optimal duration of treatment, especially for nivolumab, remains unclear, as well as the benefit of treatment beyond progression.
Third-line treatment
An algorithm for third-line systemic treatment in ccRCC is presented in Figure 3 .  In patients previously treated with VEGF-targeted therapy and an mTOR inhibitor, sorafenib has shown activity [54] . However, nivolumab or cabozantinib can be recommended in this setting. Finally, another TKI or rechallenge with the same TKI is considered as an option.
Medical treatment for non-ccRCC
Clinical data are limited in these rare histological subtypes, which are usually excluded from controlled phase III trials. Therefore, enrolment into specific clinical trials is strongly recommended. The current evidence is mainly based on small prospective studies and subgroup analyses from larger trials, which mainly focus on TKI or mTOR inhibitor testing [55] [56] . Although not providing definitive answers, these trials favoured sunitinib over the use of everolimus, indicating a similar pattern as that seen in ccRCC. These results were further supported by data from expanded access programs, retrospective series and from subgroup analysis of the temsirolimus registration trial. Overall, the most robust data exist for the use of sunitinib. These studies also suggest that patients with non-clear cell histology may benefit from treatment with everolimus, sorafenib, pazopanib or temsirolimus.
However, in most of these studies, only patients with papillary and chromophobe tumours were enrolled. More recently, clinical data on checkpoint inhibitors have been reported, which suggest clinical activity in patients with non-ccRCC and support their use in such previously treated patients. An algorithm for first-line systemic treatment in non-ccRCC is presented in Figure 4 .
After first-line therapy, there is no recommendation possible based on available data. However, at least for papillary tumours, which are the most common non-ccRCCs, the use of the ccRCC algorithm is an acceptable option.
In addition to these general recommendations, some specific situations should be considered:
 cMET inhibitors have shown activity in papillary RCC with cMET mutation or amplification [57] . Crizotinib or other cMET inhibitors such as cabozantinib appear as acceptable option instead of usual VEGF TKIs.
 Some patients with chromophobe RCC may benefit from mTOR inhibitors since mutation on chromosome 7 was shown to lead to a loss of the folliculin gene with upregulation of mTOR [9] .
 Some data suggest that sarcomatoid tumours are very inflamed tumours, usually with poor-risk features, and are sensitive to immune checkpoint inhibitors. Thus, the use of nivolumab/ipilimumab combination should be considered as a good option for these patients.
 Finally, CDCs (and also medullary carcinomas) were reported to behave more like aggressive urothelial tumours rather than RCCs and may therefore be considered for chemotherapy, although expected results are still poor.
 None of these 'genetic' recommendations can be graded, as data are limited and no clear treatment recommendation can be made for these subgroups with distinct biology. Although radiosensitivity of RCC is not perfect, this is not a radioresistant disease.
Role of radiotherapy and bisphosphonates
RT has been shown to provide good symptom palliation and local control in RCC depending on the dose that can be delivered [58] . There is a developing rationale with emerging data suggesting that the apparent radioresistance of RCC can be overcome through the ceramide pathway with the use of higher dose-per-fraction Adequate control of brain metastases prior to initiation of anti-VEGF therapy is recommended (expert opinion).
Finally, randomised data from two trials support the use of postoperative SRS following resection of one to three brain metastases, although these data should be interpreted with caution.
Multidisciplinary management is needed to optimise care for mRCC patients suffering from bone metastasis. The approach will need to be individualised to the extent of bone metastasis, its location and potential consequences (see sections above on RT palliation and spinal cord compression). In widespread mRCC bone metastasis, bisphosphonate therapy with zoledronic acid has been shown to significantly reduce skeletal related events (SREs) in patients and increase time to first SRE [64] . The receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor denosumab has been shown in a randomised trial to extend the time to first SRE by 4.3 months and was non-inferior to zoledronic acid [65] . In addition, denosumab has the convenience of subcutaneous administration with no requirement for renal monitoring or dose adjustment [I, A]. Bone-targeted therapy with either zoledronic acid or denosumab should be considered in mRCC patients with reasonable life expectancy and widespread bony metastasis, weighing the potential benefits of the treatment with the potential harms (risk of osteonecrosis of the jaw) [II, A]. Further trials are ongoing to explore its other applications.
Personalised medicine
In this disease setting, more research is needed to identify molecular markers which could lead to advances in personalised medicine. However, there is growing evidence that some biomarkers will have clinical implications in the near future, as suggested above for papillary RCC with cMET mutation.
Follow-up, long-term implications and survivorship
So far, there is no evidence that early treatment of metastasis results in better outcome of metastatic disease when compared with delayed treatment. Overall, there is no evidence that any particular follow-up protocol influences the outcome in early RCC as well as in advanced RCC.
The follow up scheme for localised RCC following surgery should depend on the therapeutic possibilities upon recurrence. CT scans of thorax and abdomen are routinely carried out, with time intervals depending on risk factors. It is recommended to perform CT scans every 3-6 months in high-risk patients for the first two years, while a yearly CT scan is probably sufficient in low-risk patients (expert opinion).
Long-term follow-up is proposed in some institutions, due to the possibility of late relapse, but its benefit has never been demonstrated [66] . Table 7 . ESMO-MCBS v1.1 [67] was used to calculate scores for new therapies/indications approved by the EMA since 1 January 2016. LoEs and grades of recommendation (GoRs) have been applied using the system shown in Table 8 .
Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty. This manuscript has been subjected to an anonymous peer review process. Reprinted with permission from [6] . 
Levels of evidence
I
Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of wellconducted randomised trials without heterogeneity II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity III Prospective cohort studies IV Retrospective cohort studies or case-control studies V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, ...), optional D Moderate evidence against efficacy or for adverse outcome, generally not recommended E Strong evidence against efficacy or for adverse outcome, never recommended a By permission of the Infectious Diseases Society of America [70] . Non-ccRCC, non-clear cell renal cell carcinoma.
